574 related articles for article (PubMed ID: 34798316)
1. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and pathological characteristics of immune mediated necrotizing myopathy].
Yang HX; Tian XL; Jiang W; Li WL; Liu QY; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):989-995. PubMed ID: 31848492
[TBL] [Abstract][Full Text] [Related]
3. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy.
Lia A; Annese T; Fornaro M; Giannini M; D'Abbicco D; Errede M; Lorusso L; Amati A; Tampoia M; Trojano M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Girolamo F
Rheumatology (Oxford); 2022 Aug; 61(8):3448-3460. PubMed ID: 34864921
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated necrotizing myopathy: clinical features and pathogenesis.
Allenbach Y; Benveniste O; Stenzel W; Boyer O
Nat Rev Rheumatol; 2020 Dec; 16(12):689-701. PubMed ID: 33093664
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
[TBL] [Abstract][Full Text] [Related]
6. Immune Mediated Necrotizing Myopathy: Where do we Stand?
Mohammed AGA; Gcelu A; Moosajee F; Botha S; Kalla AA
Curr Rheumatol Rev; 2019; 15(1):23-26. PubMed ID: 29623846
[TBL] [Abstract][Full Text] [Related]
7. Immune-Mediated Necrotizing Myopathy.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Curr Rheumatol Rep; 2018 Mar; 20(4):21. PubMed ID: 29582188
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of immune-mediated necrotizing myopathies and their treatments.
Pinal-Fernandez I; Mammen AL
Curr Opin Rheumatol; 2016 Nov; 28(6):619-24. PubMed ID: 27607340
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.
Lahaye C; Beaufrére AM; Boyer O; Drouot L; Soubrier M; Tournadre A
Joint Bone Spine; 2014 Jan; 81(1):79-82. PubMed ID: 23953224
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Features of Anti-Ku Myositis.
Oyama M; Holzer MT; Ohnuki Y; Saito Y; Nishimori Y; Suzuki S; Shiina T; Leonard-Louis S; Benveniste O; Schneider U; Stenzel W; Nishino I; Suzuki S; Uruha A
Neurology; 2024 Apr; 102(8):e209268. PubMed ID: 38547417
[TBL] [Abstract][Full Text] [Related]
11. Anti-signal recognition particle positive necrotizing myopathy-sjogren's syndrome overlap syndrome: a descriptive study on clinical and myopathology features.
Xu L; Yang MG; Hu L; Gao H; Ji S
BMC Musculoskelet Disord; 2023 Mar; 24(1):219. PubMed ID: 36959614
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies.
Cappelletti C; Brugnoni R; Bonanno S; Andreetta F; Salerno F; Canioni E; Vattemi GNA; Tonin P; Mantegazza R; Maggi L
Eur J Immunol; 2023 Nov; 53(11):e2250326. PubMed ID: 37562045
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological Features of Myositis and Necrotizing Myopathy: How to Distinguish between Myositis and Muscular Dystrophy on Muscle Pathology].
Saito Y; Nishino I
Brain Nerve; 2021 Feb; 73(2):147-159. PubMed ID: 33561829
[TBL] [Abstract][Full Text] [Related]
14. The pattern of MHC class I expression in muscle biopsies from patients with myositis and other neuromuscular disorders.
Milisenda JC; Pinal-Fernandez I; Lloyd TE; Grau-Junyent JM; Christopher-Stine L; Corse AM; Mammen AL
Rheumatology (Oxford); 2023 Sep; 62(9):3156-3160. PubMed ID: 36707996
[TBL] [Abstract][Full Text] [Related]
15. Peculiar clinicopathological features of immune-mediated necrotizing myopathies.
Allenbach Y; Benveniste O
Curr Opin Rheumatol; 2018 Nov; 30(6):655-663. PubMed ID: 30239349
[TBL] [Abstract][Full Text] [Related]
16. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
17. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy.
Julien S; van der Woning B; De Ceuninck L; Briand E; Jaworski T; Roussel G; Zoubaïri R; Allenbach Y; Benveniste O; Drouot L; Boyer O
Rheumatology (Oxford); 2023 Dec; 62(12):4006-4011. PubMed ID: 37335864
[TBL] [Abstract][Full Text] [Related]
18. Atypical skin conditions of the neck and back as a dermal manifestation of anti-HMGCR antibody-positive myopathy.
Kurashige T; Nakamura R; Murao T; Mine N; Sato M; Katsumata R; Kanaya Y; Dodo Y; Sugiura T; Ohshita T
BMC Immunol; 2024 May; 25(1):30. PubMed ID: 38734636
[TBL] [Abstract][Full Text] [Related]
19. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
Basharat P; Christopher-Stine L
Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574
[TBL] [Abstract][Full Text] [Related]
20. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child.
Mohassel P; Foley AR; Donkervoort S; Fequiere PR; Pak K; Bönnemann CG; Mammen AL
Muscle Nerve; 2017 Dec; 56(6):1177-1181. PubMed ID: 28066895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
